Akari Therapeutics (NASDAQ:AKTX) Shares Pass Below Two Hundred Day Moving Average – What’s Next?

Akari Therapeutics, Plc (NASDAQ:AKTX)’s stock price passed below its two hundred day moving average during trading on Monday . The stock has a two hundred day moving average of $1.80 and traded as low as $1.02. Akari Therapeutics shares last traded at $1.10, with a volume of 57,287 shares.

Analyst Upgrades and Downgrades

Separately, StockNews.com started coverage on Akari Therapeutics in a report on Tuesday. They set a “sell” rating on the stock.

Akari Therapeutics Trading Down 0.8 %

The business has a 50-day moving average price of $1.11 and a two-hundred day moving average price of $1.79.

About Akari Therapeutics

Akari Therapeutics, Plc, a clinical-stage biopharmaceutical company, focuses on developing advanced therapies for autoimmune and inflammatory diseases. Its lead product candidate is nomacopan, a second-generation complement inhibitor that prevents inflammatory and prothrombotic activities, including paroxysmal nocturnal hemoglobinuria, Guillain-Barré syndrome, hematopoietic stem cell transplant-associated thrombotic microangiopathy, and bullous pemphigoid, as well as pre-clinical program developing long-acting PASylated-nomacopan for treatment of geographic atrophy secondary to dry age-related macular degeneration.